- Report
- May 2024
- 134 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- February 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- January 2022
- 200 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- May 2022
- 41 Pages
Global
From €1909EUR$2,000USD£1,599GBP
Anorexia Nervosa Drug market is a subset of the Mental Disorders Drugs market. It is composed of drugs used to treat anorexia nervosa, a serious mental disorder characterized by an abnormally low body weight, an intense fear of gaining weight, and a distorted perception of body weight. Common drugs used to treat anorexia nervosa include selective serotonin reuptake inhibitors (SSRIs), antipsychotics, and mood stabilizers. These drugs are used to reduce anxiety, improve mood, and reduce the risk of relapse.
The Anorexia Nervosa Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca, and Novartis. Other companies include Sun Pharmaceuticals, Teva Pharmaceuticals, and Mylan. Show Less Read more